期刊
BIOSENSORS & BIOELECTRONICS
卷 213, 期 -, 页码 -出版社
ELSEVIER ADVANCED TECHNOLOGY
DOI: 10.1016/j.bios.2022.114449
关键词
COVID-19; Neutralizing antibody; Lateral flow immunoassay; Artificial intelligence; Polydopamine
类别
资金
- National Key Research and Development Program of China [2018YFC1707702]
- National Natural Science Foundation of China [22104119]
- Fundamental Research Funds for the Central Universities of China [xzy012019067]
- General Financial Grant from the China Post-doctoral Science Foundation [2019M663741]
- Key Program for Science and Technology Innovative Research Team in Shaanxi Province of China [2017KCT-22]
- Natural Science Foundation of Shaanxi Province of China [2021JQ-013]
An AI-assisted PDA-based LFIA platform for quantifying neutralizing antibodies produced from COVID-19 vaccinations was developed, showing sensitivity and accuracy in large-scale evaluation of vaccine effectiveness.
Currently, vaccination is the most effective medical measure to improve group immunity and prevent the rapid spread of COVID-19. Since the individual difference of vaccine effectiveness is inevitable, it is necessary to evaluate the vaccine effectiveness of every vaccinated person to ensure the appearance of herd immunity. Here, we developed an artificial intelligent (AI)-assisted colorimetric polydopamine nanoparticle (PDA)-based lateral flow immunoassay (LFIA) platform for the sensitive and accurate quantification of neutralizing antibodies produced from vaccinations. The platform integrates PDA-based LFIA and a smartphone-based reader to test the neutralizing antibodies in serum, where an AI algorithm is also developed to accurately and quantitatively analyze the results. The developed platform achieved a quantitative detection with 160 ng/mL of detection limit and 625-10000 ng/mL of detection range. Moreover, it also successfully detected totally 50 clinical serum samples, revealing a great consistency with the commercial ELISA kit. Comparing with commercial gold nanoparticle-based LFIA, our PDA-based LFIA platform showed more accurate quantification ability for the clinical serum. Therefore, we envision that the AI-assisted PDA-based LFIA platform with sensitive and accurate quantification ability is of great significance for large-scale evaluation of vaccine effectiveness and other point-of care immunoassays.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据